Amgen's Earnings Beat Shows Death Of Mass-Market Drugs
Cancer cells. Osteoporosis doesn't. Time to pay a dividend.
Cancer cells. Osteoporosis doesn't. Time to pay a dividend.
I’ve written previously about the highly wonky debate conservatives and liberals have been having on how best to curb our government’s unsustainable growth in Medicare spending. read »
Age is all about perspective. At 40, I am ancient, old to a 20 year old, but I am delightfully spry to a 60 year old. It all depends on your vantage point. So, what is your perspective when I tell you I vividly remember an episode of The Twilight Zone that has stuck with me to this day. In it, a man dies and is greeted by an angel who tells him he has died and he can have whatever he wants. He wants to go gambling - he wins every time. Luxury accommodations, beautiful women on his arm - done. [...] read »
We expect that finding good stocks will only get more and more challenging as markets come to accept that, (1) the post-recession rebound in growth is over, (2) commodity prices and inflation limit the Federal Reserve’s ability to keep interest rates artificially low for much longer and (3) the valuations on many stocks look quite full in the current environment. read »
Written by Adam Aronson read »
One of the globe's largest producers of health care products and consumer goods, Johnson & Johnson, reported higher-than-expected revenue and core profit and raised its expectations for the next fiscal year. Shares gained 2.9% after the market open Tuesday to $62.19. read »
For the pharmaceutical industry, last year was historic and grim: it was the first year ever when all of the ten most popular medicines in the U.S. were cheap generics. read »